Legal & General Group
AARD

Legal & General Group’s Aardvark Therapeutics AARD Stock Holding History

Legal & General Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.31K Sell
1,143
-145
-11% -$1.5K ﹤0.01% 3302
2025
Q4 		$16.9K Buy
1,288
+701
+119% +$8.75K ﹤0.01% 3099
2025
Q3 		$7.8K Hold
587
– – ﹤0.01% 3330
2025
Q2 		$7.94K Buy
+587
New +$6.05K ﹤0.01% 3339

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Legal & General Group's AARD Position: Q1 2026 in Review

Legal & General Group reduced its Aardvark Therapeutics (AARD) stake by 11% in Q1 2026, selling an estimated $1.5K and leaving 1,143 shares worth $4.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3302.

Legal & General Group first reported a position in AARD in Q2 2025 and has held it in 4 quarters since. The position peaked at $16.9K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Legal & General Group held 1,143 shares of Aardvark Therapeutics worth $4.31K as of Q1 2026.
  • Legal & General Group sold 145 Aardvark Therapeutics shares in Q1 2026, an estimated $1.5K.
  • Aardvark Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3302 holding.
  • Legal & General Group first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Legal & General Group's Aardvark Therapeutics position peaked at $16.9K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.